Search

Your search keyword '"Saladino, V."' showing total 111 results
Start Over Author "Saladino, V."
111 results on '"Saladino, V."'

1. High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life setting

Author

Fabbiani, M, Lombardi, A, Colaneri, M, Del Poggio, P, Perini, P, D'Ambrosio, R, Degasperi, E, Dibenedetto, C, Giorgini, A, Pasulo, L, Maggiolo, F, Castelli, F, Brambilla, P, Spinelli, O, Re, T, Lleo, A, Rumi, M, Uberti-Foppa, C, Soria, A, Aghemo, A, Lampertico, P, Baiguera, C, Schiavini, M, Fagiuoli, S, Bruno, R, Borghi, M, Soffredini, R, Perbellini, R, Gori, A, Ferroni, V, Colpani, M, Manini, M, Cologni, G, Lazzaroni, S, Vinci, M, De Nicola, S, Mazzarelli, C, Angelini Zucchetti, T, Picciotto, V, Puoti, M, Rossotti, R, Landonio, S, Magni, C, Rizzardini, G, Colella, E, Columpsi, P, Gambaro, A, Spolti, A, Magnani, C, Vigano, P, Mena, M, Villa, M, Caramma, I, Basilico, C, Capelli, F, Biagiotti, S, Mazzone, A, Saladino, V, Baldacci, M, Gatti, F, Varalli, L, Morini, L, Menzaghi, B, Farinazzo, M, Meli, R, Plaz Torres, M, Fanetti, I, Orellana, D, Zermiani, P, Zuin, M, De Bona, A, D'Arminio Monforte, A, Capretti, A, Taddei, M, Soncini, M, Spinetti, A, Zaltron, S, Pigozzi, M, Rossini, A, Pan, A, Dal Zoppo, S, Zoncada, A, Memoli, M, Salpietro, S, Hamid, H, Messina, E, Colombo, A, Giglio, O, Bonfanti, P, Molteni, C, Terreni, N, Spinzi, G, Conforti, S, Clerici, E, Menozzi, F, Buscarini, E, Centenaro, R, Corbellini, A, Noventa, F, Gritti, S, Giani, P, Fabbiani M., Lombardi A., Colaneri M., Del Poggio P., Perini P., D'Ambrosio R., Degasperi E., Dibenedetto C., Giorgini A., Pasulo L., Maggiolo F., Castelli F., Brambilla P., Spinelli O., Re T., Lleo A., Rumi M., Uberti-Foppa C., Soria A., Aghemo A., Lampertico P., Baiguera C., Schiavini M., Fagiuoli S., Bruno R., Borghi M., Soffredini R., Perbellini R., Gori A., Ferroni V., Colpani M., Manini M., Cologni G., Lazzaroni S., Vinci M., De Nicola S., Mazzarelli C., Angelini Zucchetti T., Picciotto V., Puoti M., Rossotti R., Landonio S., Magni C. F., Rizzardini G., Colella E., Columpsi P., Gambaro A., Spolti A., Magnani C., Vigano P., Mena M., Villa M., Caramma I., Basilico C., Capelli F., Biagiotti S., Mazzone A., Saladino V., Baldacci M. P., Gatti F., Varalli L., Morini L., Menzaghi B., Farinazzo M., Meli R., Plaz Torres M. C., Fanetti I., Orellana D., Zermiani P., Zuin M., De Bona A., D'Arminio Monforte A., Capretti A., Taddei M. T., Soncini M., Spinetti A., Zaltron S., Pigozzi M. G., Rossini A., Pan A., Dal Zoppo S., Zoncada A., Memoli M., Salpietro S., Hamid H., Messina E., Colombo A. E., Giglio O., Bonfanti P., Molteni C., Terreni N., Spinzi G., Conforti S., Clerici E., Menozzi F., Buscarini E., Centenaro R., Corbellini A., Noventa F., Gritti S., Giani P., Fabbiani, M, Lombardi, A, Colaneri, M, Del Poggio, P, Perini, P, D'Ambrosio, R, Degasperi, E, Dibenedetto, C, Giorgini, A, Pasulo, L, Maggiolo, F, Castelli, F, Brambilla, P, Spinelli, O, Re, T, Lleo, A, Rumi, M, Uberti-Foppa, C, Soria, A, Aghemo, A, Lampertico, P, Baiguera, C, Schiavini, M, Fagiuoli, S, Bruno, R, Borghi, M, Soffredini, R, Perbellini, R, Gori, A, Ferroni, V, Colpani, M, Manini, M, Cologni, G, Lazzaroni, S, Vinci, M, De Nicola, S, Mazzarelli, C, Angelini Zucchetti, T, Picciotto, V, Puoti, M, Rossotti, R, Landonio, S, Magni, C, Rizzardini, G, Colella, E, Columpsi, P, Gambaro, A, Spolti, A, Magnani, C, Vigano, P, Mena, M, Villa, M, Caramma, I, Basilico, C, Capelli, F, Biagiotti, S, Mazzone, A, Saladino, V, Baldacci, M, Gatti, F, Varalli, L, Morini, L, Menzaghi, B, Farinazzo, M, Meli, R, Plaz Torres, M, Fanetti, I, Orellana, D, Zermiani, P, Zuin, M, De Bona, A, D'Arminio Monforte, A, Capretti, A, Taddei, M, Soncini, M, Spinetti, A, Zaltron, S, Pigozzi, M, Rossini, A, Pan, A, Dal Zoppo, S, Zoncada, A, Memoli, M, Salpietro, S, Hamid, H, Messina, E, Colombo, A, Giglio, O, Bonfanti, P, Molteni, C, Terreni, N, Spinzi, G, Conforti, S, Clerici, E, Menozzi, F, Buscarini, E, Centenaro, R, Corbellini, A, Noventa, F, Gritti, S, Giani, P, Fabbiani M., Lombardi A., Colaneri M., Del Poggio P., Perini P., D'Ambrosio R., Degasperi E., Dibenedetto C., Giorgini A., Pasulo L., Maggiolo F., Castelli F., Brambilla P., Spinelli O., Re T., Lleo A., Rumi M., Uberti-Foppa C., Soria A., Aghemo A., Lampertico P., Baiguera C., Schiavini M., Fagiuoli S., Bruno R., Borghi M., Soffredini R., Perbellini R., Gori A., Ferroni V., Colpani M., Manini M., Cologni G., Lazzaroni S., Vinci M., De Nicola S., Mazzarelli C., Angelini Zucchetti T., Picciotto V., Puoti M., Rossotti R., Landonio S., Magni C. F., Rizzardini G., Colella E., Columpsi P., Gambaro A., Spolti A., Magnani C., Vigano P., Mena M., Villa M., Caramma I., Basilico C., Capelli F., Biagiotti S., Mazzone A., Saladino V., Baldacci M. P., Gatti F., Varalli L., Morini L., Menzaghi B., Farinazzo M., Meli R., Plaz Torres M. C., Fanetti I., Orellana D., Zermiani P., Zuin M., De Bona A., D'Arminio Monforte A., Capretti A., Taddei M. T., Soncini M., Spinetti A., Zaltron S., Pigozzi M. G., Rossini A., Pan A., Dal Zoppo S., Zoncada A., Memoli M., Salpietro S., Hamid H., Messina E., Colombo A. E., Giglio O., Bonfanti P., Molteni C., Terreni N., Spinzi G., Conforti S., Clerici E., Menozzi F., Buscarini E., Centenaro R., Corbellini A., Noventa F., Gritti S., and Giani P.

Abstract

In routine clinical practice, hepatitis C virus-infected patients can prematurely discontinue the prescribed regimen for several reasons. The aim of our study was to investigate sustained virological response (SVR12) rates in patients who prematurely discontinued directly acting antiviral (DAA) regimens and to assess the shortest effective duration of DAA able to lead to SVR12. We retrospectively collected the SVR rates of patients, registered in the NAVIGATORE-Lombardia Network database from January 2015, who discontinued DAAs before the predefined end of treatment. Overall, we included 365 patients, males were the majority (213, 58.4%), mean age was 60.5 years, and 53 (14.5%) patients were HIV-co-infected. Liver cirrhosis was observed in 251 (68.8%) subjects, and the most represented genotypes were 1b (n = 168, 46%) and 3 (n = 59, 16.2%). DAA was discontinued a median of 1 (IQR 1–4) weeks before the predefined EOT, with 164 (44.9%) patients stopping DAAs at least 2 weeks before the planned schedule. In patients with F0–F3 liver fibrosis, lower rates of SVR12 were observed in patients treated for <4 weeks: 50% (n = 2/4) vs. 99.1% (n = 109/110) for ≥4 weeks, p = 0.003. In patients with liver cirrhosis, lower rates of SVR12 were observed in patients treated <8 weeks: 83.3% (n = 25/30) vs. 94.6% (n = 209/221) for ≥8 weeks, p = 0.038. Despite premature discontinuation of DAA, high SVR12 rates were observed in a real-life setting for treatment lasting at least 4 weeks in patients with liver fibrosis F0–F3 and 8 weeks in those with liver cirrhosis. On this basis, feasibility of reducing DAA treatment duration should be explored in randomized clinical trials.

Published
2021

2. High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life setting

Author

Fabbiani M., Lombardi A., Colaneri M., Del Poggio P., Perini P., D'Ambrosio R., Degasperi E., Dibenedetto C., Giorgini A., Pasulo L., Maggiolo F., Castelli F., Brambilla P., Spinelli O., Re T., Lleo A., Rumi M., Uberti-Foppa C., Soria A., Aghemo A., Lampertico P., Baiguera C., Schiavini M., Fagiuoli S., Bruno R., Borghi M., Soffredini R., Perbellini R., Gori A., Ferroni V., Colpani M., Manini M., Cologni G., Lazzaroni S., Vinci M., De Nicola S., Mazzarelli C., Angelini Zucchetti T., Picciotto V., Puoti M., Rossotti R., Landonio S., Magni C. F., Rizzardini G., Colella E., Columpsi P., Gambaro A., Spolti A., Magnani C., Vigano P., Mena M., Villa M., Caramma I., Basilico C., Capelli F., Biagiotti S., Mazzone A., Saladino V., Baldacci M. P., Gatti F., Varalli L., Morini L., Menzaghi B., Farinazzo M., Meli R., Plaz Torres M. C., Fanetti I., Orellana D., Zermiani P., Zuin M., De Bona A., D'Arminio Monforte A., Capretti A., Taddei M. T., Soncini M., Spinetti A., Zaltron S., Pigozzi M. G., Rossini A., Pan A., Dal Zoppo S., Zoncada A., Memoli M., Salpietro S., Hamid H., Messina E., Colombo A. E., Giglio O., Bonfanti P., Molteni C., Terreni N., Spinzi G., Conforti S., Clerici E., Menozzi F., Buscarini E., Centenaro R., Corbellini A., Noventa F., Gritti S., Giani P., Fabbiani, Massimiliano, Lombardi, Andrea, Colaneri, Marta, Del Poggio, Paolo, Perini, Paolo, D'Ambrosio, Roberta, Degasperi, Elisabetta, Dibenedetto, Clara, Giorgini, Alessia, Pasulo, Luisa, Maggiolo, Franco, Castelli, Francesco, Brambilla, Paola, Spinelli, Ombretta, Tiziana, Re, Lleo, Ana, Rumi, Mariagrazia, Uberti-Foppa, Caterina, Soria, Alessandro, Aghemo, Alessio, Lampertico, Pietro, Baiguera, Chiara, Schiavini, Monica, Fagiuoli, Stefano, Bruno, Raffaele, Fabbiani, M, Lombardi, A, Colaneri, M, Del Poggio, P, Perini, P, D'Ambrosio, R, Degasperi, E, Dibenedetto, C, Giorgini, A, Pasulo, L, Maggiolo, F, Castelli, F, Brambilla, P, Spinelli, O, Re, T, Lleo, A, Rumi, M, Uberti-Foppa, C, Soria, A, Aghemo, A, Lampertico, P, Baiguera, C, Schiavini, M, Fagiuoli, S, Bruno, R, Borghi, M, Soffredini, R, Perbellini, R, Gori, A, Ferroni, V, Colpani, M, Manini, M, Cologni, G, Lazzaroni, S, Vinci, M, De Nicola, S, Mazzarelli, C, Angelini Zucchetti, T, Picciotto, V, Puoti, M, Rossotti, R, Landonio, S, Magni, C, Rizzardini, G, Colella, E, Columpsi, P, Gambaro, A, Spolti, A, Magnani, C, Vigano, P, Mena, M, Villa, M, Caramma, I, Basilico, C, Capelli, F, Biagiotti, S, Mazzone, A, Saladino, V, Baldacci, M, Gatti, F, Varalli, L, Morini, L, Menzaghi, B, Farinazzo, M, Meli, R, Plaz Torres, M, Fanetti, I, Orellana, D, Zermiani, P, Zuin, M, De Bona, A, D'Arminio Monforte, A, Capretti, A, Taddei, M, Soncini, M, Spinetti, A, Zaltron, S, Pigozzi, M, Rossini, A, Pan, A, Dal Zoppo, S, Zoncada, A, Memoli, M, Salpietro, S, Hamid, H, Messina, E, Colombo, A, Giglio, O, Bonfanti, P, Molteni, C, Terreni, N, Spinzi, G, Conforti, S, Clerici, E, Menozzi, F, Buscarini, E, Centenaro, R, Corbellini, A, Noventa, F, Gritti, S, and Giani, P

Subjects
Simeprevir, Male, medicine.medical_specialty, Cirrhosis, SVR, Sofosbuvir, Sustained Virologic Response, liver cirrhosis, antiviral treatment, Hepacivirus, Antiviral Agents, law.invention, Randomized controlled trial, law, Virology, Internal medicine, Medicine, Humans, chronic hepatitis C, Prospective cohort study, DAA, Retrospective Studies, Hepatology, liver cirrhosi, business.industry, Hepatitis C, Hepatitis C, Chronic, Middle Aged, medicine.disease, Discontinuation, Regimen, Infectious Diseases, Treatment Outcome, business, medicine.drug
Abstract

In routine clinical practice, hepatitis C virus-infected patients can prematurely discontinue the prescribed regimen for several reasons. The aim of our study was to investigate sustained virological response (SVR12) rates in patients who prematurely discontinued directly acting antiviral (DAA) regimens and to assess the shortest effective duration of DAA able to lead to SVR12. We retrospectively collected the SVR rates of patients, registered in the NAVIGATORE-Lombardia Network database from January 2015, who discontinued DAAs before the predefined end of treatment. Overall, we included 365 patients, males were the majority (213, 58.4%), mean age was 60.5years, and 53 (14.5%) patients were HIV-co-infected. Liver cirrhosis was observed in 251 (68.8%) subjects, and the most represented genotypes were 1b (n=168, 46%) and 3 (n=59, 16.2%). DAA was discontinued a median of 1 (IQR 1–4) weeks before the predefined EOT, with 164 (44.9%) patients stopping DAAs at least 2weeks before the planned schedule. In patients with F0–F3 liver fibrosis, lower rates of SVR12 were observed in patients treated for

Published
2021

14. Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C

Author

D'Ambrosio, R, Pasulo, L, Puoti, M, Vinci, M, Schiavini, M, Lazzaroni, S, Soria, A, Gatti, F, Menzaghi, B, Aghemo, A, Capelli, F, Rumi, M, Morini, L, Giorgini, A, Pigozzi, M, Rossini, A, Maggiolo, F, Pan, A, Memoli, M, Spinelli, O, Del Poggio, P, Saladino, V, Spinetti, A, De Bona, A, Capretti, A, Uberti-Foppa, C, Bonfanti, P, Terreni, N, Menozzi, F, Colombo, A, Giglio, O, Centenaro, R, Borghi, M, Baiguera, C, Picciotto, V, Landonio, S, Gori, A, Magnani, C, Noventa, F, Paolucci, S, Lampertico, P, Fagiuoli, S, D'Ambrosio, Roberta, Pasulo, Luisa, Puoti, Massimo, Vinci, Maria, Schiavini, Monica, Lazzaroni, Sergio, Soria, Alessandro, Gatti, Federico, Menzaghi, Barbara, Aghemo, Alessio, Capelli, Francesca, Rumi, Maria Grazia, Morini, Lorenzo, Giorgini, Alessia, Pigozzi, Marie Graciella, Rossini, Angelo, Maggiolo, Franco, Pan, Angelo, Memoli, Massimo, Spinelli, Ombretta, Del Poggio, Paolo, Saladino, Valeria, Spinetti, Angiola, De Bona, Anna, Capretti, Andrea, Uberti-Foppa, Caterina, Bonfanti, Paolo, Terreni, Natalia, Menozzi, Fernanda, Colombo, Alberto Eraldo, Giglio, Omar, Centenaro, Riccardo, Borghi, Marta, Baiguera, Chiara, Picciotto, Viviana, Landonio, Simona, Gori, Andrea, Magnani, Carlo, Noventa, Franco, Paolucci, Stefania, Lampertico, Pietro, Fagiuoli, Stefano, D'Ambrosio, R, Pasulo, L, Puoti, M, Vinci, M, Schiavini, M, Lazzaroni, S, Soria, A, Gatti, F, Menzaghi, B, Aghemo, A, Capelli, F, Rumi, M, Morini, L, Giorgini, A, Pigozzi, M, Rossini, A, Maggiolo, F, Pan, A, Memoli, M, Spinelli, O, Del Poggio, P, Saladino, V, Spinetti, A, De Bona, A, Capretti, A, Uberti-Foppa, C, Bonfanti, P, Terreni, N, Menozzi, F, Colombo, A, Giglio, O, Centenaro, R, Borghi, M, Baiguera, C, Picciotto, V, Landonio, S, Gori, A, Magnani, C, Noventa, F, Paolucci, S, Lampertico, P, Fagiuoli, S, D'Ambrosio, Roberta, Pasulo, Luisa, Puoti, Massimo, Vinci, Maria, Schiavini, Monica, Lazzaroni, Sergio, Soria, Alessandro, Gatti, Federico, Menzaghi, Barbara, Aghemo, Alessio, Capelli, Francesca, Rumi, Maria Grazia, Morini, Lorenzo, Giorgini, Alessia, Pigozzi, Marie Graciella, Rossini, Angelo, Maggiolo, Franco, Pan, Angelo, Memoli, Massimo, Spinelli, Ombretta, Del Poggio, Paolo, Saladino, Valeria, Spinetti, Angiola, De Bona, Anna, Capretti, Andrea, Uberti-Foppa, Caterina, Bonfanti, Paolo, Terreni, Natalia, Menozzi, Fernanda, Colombo, Alberto Eraldo, Giglio, Omar, Centenaro, Riccardo, Borghi, Marta, Baiguera, Chiara, Picciotto, Viviana, Landonio, Simona, Gori, Andrea, Magnani, Carlo, Noventa, Franco, Paolucci, Stefania, Lampertico, Pietro, and Fagiuoli, Stefano

Abstract

Background and Aims: The efficacy and safety of glecaprevir/pibrentasvir (G/P) for patients infected with hepatitis C virus (HCV) have only been investigated in clinical trials, with no real-world data currently available. The aim of our study was to investigate the effectiveness and safety of G/P in a real-world setting.Methods: All patients with HCV consecutively starting G/P between October 2017 and January 2018 within the NAVIGATORE-Lombardia Network were analyzed. G/P was administered according to drug label (8, 12 or 16 weeks). Fibrosis was staged either histologically or by liver stiffness measurement. Sustained virological response (SVR) was defined as undetectable HCV-RNA 12 weeks after the end of treatment.Results: A total of 723 patients (50% males) were treated with G/P, 89% for 8 weeks. The median age of our cohort was median liver stiffness measurement of 6.1 kPa; 84% were F0-2 and 16% were interferon-experienced. Median HCV-RNA was 1,102,600 IU/ml, and 49% of patients had HCV genotype 1 (32% 1b), 28% genotype 2, 10% genotype 3 and 13% genotype 4. The median estimated glomerular filtration rate was 90.2 ml/min, platelet count 209x10(3)/mm(3) and albumin 4.3 g/dl. The SVR rates were 94% in intention-to-treat and 99.3% in per protocol analysis (8-week vs. 12 or 16-week: 99.2% vs. 100%). Five patients failed therapy because of post-treatment relapse; a post-treatment NS5A resistance-associated substitution was detected in 1 case. SVR rates were lower in males (p = 0.002) and in HCV genotype-3 (p = 0.046) patients treated for 8 weeks, but independent of treatment duration, fibrosis stage, baseline HCV-RNA, HIV co-infection, chronic kidney disease stage and viral kinetics. Mild adverse events were reported in 8.3% of the patients, and 0.7% of them prematurely withdrew treatment. Three patients died of drug-unrelated causes.Conclusions: In a large real-world cohort of Italian patients, we confirmed the excellent effectiveness and safety of G/P administered f

Published
2019

22. Topoisomerase II alpha and TLE3 as predictive markers of response to anthracycline and taxane-containing regimens for neoadjuvant chemotherapy in breast cancer

Author

Susini T, Berti B, Carriero C, Tavella K, Nori J, Vanzi E, Molino C, Di Tommaso M, Santini M, Saladino V, and Bianchi S

Subjects
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, lcsh:RC254-282
Abstract

Tommaso Susini,1 Barbara Berti,1 Carlo Carriero,1 Ketty Tavella,2 Jacopo Nori,3 Ermanno Vanzi,3 Cecilia Molino,1 Mariarosaria Di Tommaso,1 Marco Santini,1 Valeria Saladino,4 Simonetta Bianchi4 1Department of Health Science, Gynecology Section, 2Department of Health Science, Chemotherapy Section, University of Florence, Italy; 3Diagnostic Senology Unit, Azienda Ospedaliera-Universitaria Careggi, Florence, Italy; 4Department of Surgery and Translational Medicine, Pathology Unit, University of Florence, Italy Purpose: Anthracyclines and taxanes are considered the standard for neoadjuvant chemotherapy of breast cancer, although they are often associated with serious side effects and wide variability of individual response. In this study, we analyzed the value of topoisomerase II alpha (TOP2A) and transducin-like enhancer of split 3 (TLE3) as predictive markers of response to therapy with anthracyclines and taxanes. Materials and methods: TOP2A and TLE3 protein expressions were evaluated using immunohistochemistry on 28 samples, obtained by core needle biopsy in patients with locally advanced breast carcinoma, subsequently subjected to epirubicin- and paclitaxel-based neoadjuvant chemotherapy. The immunohistochemical staining was correlated with the clinical response measured by the tumor size reduction evaluated by breast magnetic resonance imaging, prior and after chemotherapy, and by pathologic evaluation of the surgical specimen. Results: Neoadjuvant chemotherapy achieved a size reduction in 26/28 tumors (92.9%), with an average percentage decrease of 45.6%. A downstaging was achieved in 71.4% of the cases of locally advanced carcinoma. TOP2A positivity was correlated with a greater reduction in tumor diameter (P=0.06); negative staining for TLE3 was predictive of a better response to neoadjuvant chemotherapy (P=0.07). A higher reduction in tumor diameter (P=0.03) was also found for tumors that were concurrently TLE3-negative and TOP2A-positive. Conclusion: TOP2A and TLE3 showed a correlation with response to neoadjuvant chemotherapy. While TOP2A is a well-known marker of response to anthracyclines-based chemotherapy, TLE3 is a new putative predictor of response to taxanes. Data from the current study suggest that TOP2A and TLE3 warrant further investigation in a larger series as predictors of response to neoadjuvant chemotherapy for locally advanced breast carcinoma. Keywords: breast carcinoma, advanced stage disease, immunohistochemical markers

Published
2014

28. P.10.5: Complications and Early Mortality in Percutaneous Endoscopic Gastrostomy Placement in Lombardy: A Multicenter Prospective Study

Author

Anderloni, A., primary, Brazaghi, F., additional, Meucci, G., additional, Marino, R., additional, Amato, L., additional, Frigerio, M., additional, Saladino, V., additional, Toldi, A., additional, Manfredi, G., additional, Redaelli, A., additional, Feliziani, M., additional, De Roberto, G., additional, Boni, F., additional, Sacchi, G., additional, Mosca, D., additional, Devani, M., additional, Arena, M., additional, Massidda, M., additional, Zanoni, P., additional, Ciscato, C., additional, Casini, V., additional, Beretta, P., additional, Forti, E., additional, Salerno, R., additional, Caramia, V., additional, Lollo, G., additional, Bianchetti, M., additional, Tomba, C., additional, Di Leo, M., additional, Soncini, M., additional, Maconi, G., additional, Manes, G., additional, and Gullotta, R., additional

Published
2017
Full Text
View/download PDF

29. The Italian Registry of Therapeutic Apheresis: Granulocyte_Monocyte Apheresis in the Treatment of Inflammatory Bowel Disease. A Multicentric Study

Author

Passalacqua, S, Ferraro, Pm, Bresci, G, D'Ovidio, V, Astegiano, M, Principi, M, Testa, R, D'Incà, R, Valpiani, D, Armuzzi, A, Sablich, R, Cavallaro, F, Costa, F, Di Leo, V, Colombo, E, Santini, A, Aratari, A, Lecis, P, Saladino, V, Riegler, G, Marco, M, Calella, F, Ricci, Chiara, Guidi, Ml, Repaci, G, and Silla, M.

Subjects
Treatment, Registry, Crohn Disease, Apheresis, Ulcerative Colitis, Ulcerative Colitis, Apheresis
Published
2011

31. Increased thrombin generation in inflammatory bowel disease

Author

Saladino, V., Villa, F., Chantarangkul, V., Saibeni, S., Vecchi, M., Bruno, S., De Franchis, R., Sei, C., Mannucci, P.M., Tripodi, A., and Rondonotti, E.

Subjects
Settore MED/12 - Gastroenterologia, Settore MED/09 - Medicina Interna, Settore BIO/12 - Biochimica Clinica e Biologia Molecolare Clinica
Published
2008

47. Cardiac risk stratification in elective non-cardiac surgery: Role of NT-proBNP

Author

Novo, G., Egle Corrado, Tortorici, E., Novo, A., Agrusa, A., Saladino, V., Marturana, I., Lentini, R., Ferrandes, M., Visconti, C., Massenti, F., D Arienzo, M., Vitale, F., Gulotta, G., Novo, S., Novo, G, Corrado, E, Tortorici, E, Novo, A, Agrusa, A, Saladino, V, Marturana, I, Lentini, R, Ferrandes, M, Visconti, C, Massenti, F, D'Arienzo, M, Vitale, F, Gulotta, G, and Novo, S

Subjects
Male, Chi-Square Distribution, Time Factors, Middle Aged, Risk Assessment, Peptide Fragments, Up-Regulation, Logistic Models, Treatment Outcome, Italy, NT-proBNP, Cardiovascular Diseases, Elective Surgical Procedures, Predictive Value of Tests, Risk Factors, Surgical Procedures, Operative, Natriuretic Peptide, Brain, Preoperative Period, Odds Ratio, Humans, Female, Biomarkers, Aged
Abstract

AIM: The aim of the study was to investigate the utility of NT-proBNP measurement for the stratification of presurgical cardiac risk. METHODS: Cardiac risk before elective non-cardiac surgery was evaluated in 82 consecutive patients. From each patient a venous blood sample was drawn to determinate NT-proBNP levels. Patients were followed up over three months in order to detect the occurrence of cardiac adverse events. RESULTS: NT-proBNP was positively correlated (P

48. Open mini-invasive cholecystectomy in high risk elderly. A review of 121 consecutive procedures

Author

Amato, G., Giuseppe SALAMONE, Romano, G., Agrusa, A., Saladino, V., Gulotta, G., Amato, G, Salamone, G, Romano, G, Agrusa, A, Saladino, V, and Gulotta, G

Subjects
Aged, 80 and over, Male, Laparotomy, Time Factors, Cost-Benefit Analysis, Frail Elderly, Length of Stay, Middle Aged, Risk Assessment, Radiography, Settore MED/18 - Chirurgia Generale, Treatment Outcome, Cholecystectomy, Laparoscopic, Cholelithiasis, Risk Factors, Humans, Minimally Invasive Surgical Procedures, Cholecystectomy, Female, open mini-invasive cholecystectomy, Aged, Retrospective Studies
Abstract

INTRODUCTION: the report describes the features of a low cost, open mini-invasive procedure for cholecystectomy in a sample of 121 consecutive high risk elderly (ASA score 3 to 5). PATIENTS AND METHODS: the surgery is performed through a 3 - 4 cm right subcostal skin incision. An optimal exposition of the operating field was achieved thanks to an innovative three valve retractor. RESULTS: a mean hospital stay of 3,02 days, low complication rate and 2,4% mortality are the results of the described procedure. CONCLUSIONS: in high risk elderly the results are extremely encouraging, particularly in comparison with both laparoscopic and traditional open cholecystectomy. The open minisurgical cholecystectomy could be considered a cost-effective alternative to laparoscopy, with excellent results in this subset of patients. The described mini-surgical procedure can also integrate the laparoscopic in case of conversion.

49. Laboratory of FORS and MO

Author

M. L. Saladino, V. Ciaramitaro, E. Caponetti, and M.L. Saladino, V. Ciaramitaro

Subjects
FORS, Settore CHIM/02 - Chimica Fisica
Abstract

In this laboratory activity, the Fiber Optic Reflectance Spectroscopy (FORS) and the Optical Microscopy (MO) techniques will be introduced. After a brief introduction about the theory, instrumentations and applications of both techniques, the students will see the application of the following equipment: -Digivision 1.3 megapixel USB digital optical microscope -Ocean Optics USB2000 + XR1 portable reflection UV-vis spectrophotometer with DH-mini UV-Vis-NIR source and reflection probe. The acquisition of MO images and of FORS spectra will be performed on pigments of some archeological ceramics, stones with and without a protective and on patina of metal alloys. The MO images of each artifacts will be discussed. Data analysis of FORS spectra will be illustrated. The colour parameters will be also calculated and some considerations about their meaning will be made.

Published
2020

50. Immunotherapy targeting colon cancer stem cells

Author

Vitanna Saladino, Giorgio Stassi, Marisa Spina, Francesco Dieli, Flora Iovino, Serena Meraviglia, Matilde Todaro, Valentina Orlando, Iovino, F, Meraviglia, S, Spina, M, Orlando, V, Saladino, V, Dieli, F, Stassi, G, and Todaro, M

Subjects
cancer stem cells, Adoptive cell transfer, T-Lymphocytes, T cell, Immunology, Biology, Cell therapy, NK-92, T-Lymphocyte Subsets, Cancer stem cell, medicine, gamma delta T cells, Humans, Immunology and Allergy, NK cell, Settore MED/04 - Patologia Generale, colon, cancer, stem cells, chemoresistance, Receptors, Antigen, T-Cell, gamma-delta, Suicide gene, Killer Cells, Natural, medicine.anatomical_structure, Oncology, Colonic Neoplasms, Cancer cell, Neoplastic Stem Cells, Immunotherapy, gamma delta T cells, cancer stem cells, chemoresistance, immunotherapy, NK cell, Stem cell
Abstract

In the last 10 years, cancer stem cells have interested the scientific community because this small tumorigenic population is also associated with tumor progression in human patients and specific targeting of cancer stem cells could be a strategy to eradicate cancers currently resistant to conventional therapy. Clinical studies have recently demonstrated that adding immune therapy to chemotherapy has survival benefits in comparison with chemotherapy alone that can sensitize tumors to immune cell-mediated killing (e.g., increasing sensitivity of tumor cells to subsequent cytotoxicity by T cells via upregulation of death receptors DR5 and Fas). However, loss of MHC molecules is often observed in cancer cells, rendering tumor cells resistant to CD8 T-cell-mediated cytotoxicity. For this reason, we review the role of other T-cell subsets, such as γδ T and NK cells that are able to efficiently recognize and kill tumor cells and that could be used in passive or active immunotherapy in cancer stem cell eradication.

Published
2011

Catalog

Books, media, physical & digital resources
See catalog results